@article {Chanteux778, author = {Hugues Chanteux and Maria Rosa and Claude Delatour and Johan Nicola{\"\i} and Eric Gillent and Sylvie Dell{\textquoteright}Aiera and Anna-Lena Ungell}, title = {Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes}, volume = {48}, number = {9}, pages = {778--787}, year = {2020}, doi = {10.1124/dmd.120.000017}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {Early determination of CYP3A4/5 contribution to the clearance of new chemical entities is critical to inform on the risk of drug-drug interactions with CYP3A inhibitors and inducers. Several in vitro approaches (recombinant P450 enzymes, correlation analysis, chemical and antibody inhibition in human liver microsomes) are available, but they are usually labor-intensive and/or suffer from specific limitations. In the present study, we have validated the use of azamulin as a specific CYP3A inhibitor in human hepatocytes. Azamulin (3 {\textmu}M) was found to significantly inhibit CYP3A4/5 (\>90\%), whereas other P450 enzymes were not affected (less than 20\% inhibition). Because human hepatocytes were used as a test system, the effect of azamulin on other key drug-metabolizing enzymes (aldehyde oxidase, carboxylesterase, UGT, flavin monooxygenase, and sulfotransferase) was also investigated. Apart from some UGTs showing minor inhibition (\~{}20\%{\textendash}30\%), none of these non-P450 enzymes were inhibited by azamulin. Use of CYP3A5-genotyped human hepatocyte batches in combination with CYP3cide demonstrated that azamulin (at 3 {\textmu}M) inhibits both CYP3A4 and CYP3A5 enzymes. Finally, 11 compounds with known in vivo CYP3A4/5 contribution have been evaluated in this human hepatocyte assay. Results showed that the effect of azamulin on the in vitro intrinsic clearance of these known CYP3A4/5 substrates was predictive of the in vivo CYP3A4/5 contribution. Overall, the study showed that human hepatocytes treated with azamulin provide a fast and accurate estimation of CYP3A4/5 contribution in metabolic clearance of new chemical entities.SIGNIFICANCE STATEMENT Accurate estimation of CYP3A4/5 contribution in drug clearance is essential to anticipate risk of drug-drug interactions and select the appropriate candidate for clinical development. The present study validated the use of azamulin as selective CYP3A4/5 inhibitor in suspended human hepatocytes and demonstrated that this novel approach provides a direct and accurate determination of the contribution of CYP3A4/5 (fraction metabolized by CYP3A4/5) in the metabolic clearance of new chemical entities.}, issn = {0090-9556}, URL = {https://dmd.aspetjournals.org/content/48/9/778}, eprint = {https://dmd.aspetjournals.org/content/48/9/778.full.pdf}, journal = {Drug Metabolism and Disposition} }